Shopping Cart 0
Cart Subtotal
USD 0

Generics in India

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 350

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 700

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 1050
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Generics in India

Summary

Generics in India industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the India generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

- The Indian generics market had total revenues of USD 14.4bn in 2017, representing a compound annual growth rate (CAGR) of 11.6% between 2013 and 2017.

- Market consumption volume increased with a CAGR of 0.8% between 2013 and 2017, to reach a total of 95.5% in 2017.

- India has the third largest market in the Asia-Pacific region and made 12.4% of the region's value in 2017.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in India

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in India

- Leading company profiles reveal details of key generics market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the India generics market with five year forecasts by both value and volume

Reasons to buy

- What was the size of the India generics market by value in 2017?

- What will be the size of the India generics market in 2022?

- What factors are affecting the strength of competition in the India generics market?

- How has the market performed over the last five years?

- How large is India's generics market in relation to its regional counterparts?

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary 2

Market value 2

Market value forecast 2

Market volume 2

Market volume forecast 2

Geography segmentation 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 9

Market value 9

Market volume 10

Market Segmentation 11

Geography segmentation 11

Market Outlook 12

Market value forecast 12

Market volume forecast 13

Five Forces Analysis 14

Summary 14

Buyer power 15

Supplier power 16

New entrants 17

Threat of substitutes 18

Degree of rivalry 19

Leading Companies 20

Aurobindo Pharma Limited 20

Cipla Limited 23

Lupin Ltd 26

Sun Pharmaceutical Industries Ltd 30

Macroeconomic Indicators 33

Country data 33

Methodology 35

Industry associations 36

Related MarketLine research 36

Appendix 37

About MarketLine 37


List Of Figure

List of Figures

Figure 1: India generics market value: USD million, 2013-17

Figure 2: India generics market volume: % of total pharma, 2013-17

Figure 3: India generics market geography segmentation: % share, by value, 2017

Figure 4: India generics market value forecast: USD million, 2017-22

Figure 5: India generics market volume forecast: % of total pharma, 2017-22

Figure 6: Forces driving competition in the generics market in India, 2017

Figure 7: Drivers of buyer power in the generics market in India, 2017

Figure 8: Drivers of supplier power in the generics market in India, 2017

Figure 9: Factors influencing the likelihood of new entrants in the generics market in India, 2017

Figure 10: Factors influencing the threat of substitutes in the generics market in India, 2017

Figure 11: Drivers of degree of rivalry in the generics market in India, 2017

Figure 12: Aurobindo Pharma Limited: revenues & profitability

Figure 13: Aurobindo Pharma Limited: assets & liabilities

Figure 14: Cipla Limited: revenues & profitability

Figure 15: Cipla Limited: assets & liabilities

Figure 16: Lupin Ltd: revenues & profitability

Figure 17: Lupin Ltd: assets & liabilities

Figure 18: Sun Pharmaceutical Industries Ltd: revenues & profitability

Figure 19: Sun Pharmaceutical Industries Ltd: assets & liabilities


List Of Table

List of Tables

Table 1: India generics market value: USD million, 2013-17

Table 2: India generics market volume: % of total pharma, 2013-17

Table 3: India generics market geography segmentation: USD million, 2017

Table 4: India generics market value forecast: USD million, 2017-22

Table 5: India generics market volume forecast: % of total pharma, 2017-22

Table 6: Aurobindo Pharma Limited: key facts

Table 7: Aurobindo Pharma Limited: key financials (USD )

Table 8: Aurobindo Pharma Limited: key financials (Rs.)

Table 9: Aurobindo Pharma Limited: key financial ratios

Table 10: Cipla Limited: key facts

Table 11: Cipla Limited: key financials (USD )

Table 12: Cipla Limited: key financials (Rs.)

Table 13: Cipla Limited: key financial ratios

Table 14: Lupin Ltd: key facts

Table 15: Lupin Ltd: key financials (USD )

Table 16: Lupin Ltd: key financials (Rs.)

Table 17: Lupin Ltd: key financial ratios

Table 18: Sun Pharmaceutical Industries Ltd: key facts

Table 19: Sun Pharmaceutical Industries Ltd: key financials (USD )

Table 20: Sun Pharmaceutical Industries Ltd: key financials (Rs.)

Table 21: Sun Pharmaceutical Industries Ltd: key financial ratios

Table 22: India size of population (million), 2013-17

Table 23: India gdp (constant 2005 prices, USD billion), 2013-17

Table 24: India gdp (current prices, USD billion), 2013-17

Table 25: India inflation, 2013-17

Table 26: India consumer price index (absolute), 2013-17

Table 27: India exchange rate, 2013-17

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Generics, MarketLine, India


Companies

Aurobindo Pharma Limited

Cipla Limited

Lupin Ltd

Sun Pharmaceutical Industries Ltd